ECJ ruling opens path to reclaim VAT on entertainment abroad

29 March 2009

A small window has been opened for exporters to reclaim value-added tax on overseas business entertainment following a decision in the European  Court of Justice. Particularly for the UK's pharmaceutical industry,  which is one of the country's biggest exporters, this could mean talking  about significant amounts of money.

The case is that of Danfoss and Anglo-Swedish drug major AstraZeneca,  which was heard at the European Court. In brief, UK-based AstraZeneca  had provided in-house catering facilities for business meetings with  international manufacturer, Danfoss. According to the ECJ, such lunches  have a business purpose and therefore the VAT should be deductible.

According to Barry Stocks, VAT expert and a director with BTG Tax in  Manchester, UK, it is worth looking into the case because "this judgment  has given businesses a brief opportunity to recover previously  unclaimed VAT input tax - potentially a significant sum of money for the  region's exporters. It is a really positive decision for businesses that  encourage international trade and build relationships with an  international client base."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight